References for

*The Online Action Plan*

*A Year of Ideas to Keep You going*

1. Chandler, S., et al., *Parent-reported gastro-intestinal symptoms in children with autism spectrum disorders.* J Autism Dev Disord, 2013. **43**(12): p. 2737-47.
2. Keshavarz Afshar, M., et al., *Lavender fragrance essential oil and the quality of sleep in postpartum women.* Iran Red Crescent Med J, 2015. **17**(4): p. e25880.
3. Field, T., et al., *Lavender bath oil reduces stress and crying and enhances sleep in very young infants.* Early Hum Dev, 2008. **84**(6): p. 399-401.
4. Dietrich, C.G., T. Kottmann, and M. Alavi, *Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea.* World J Gastroenterol, 2014. **20**(42): p. 15837-44.
5. Can, M., et al., *Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study.* Med Sci Monit, 2006. **12**(4): p. PI19-22.
6. Micklefield, G., *[Saccharomyces boulardii in the treatment and prevention of antibiotic-associated diarrhea].* MMW Fortschr Med, 2014. **156 Suppl 1**: p. 18-22.
7. Flora, K., et al., *Milk thistle (Silybum marianum) for the therapy of liver disease.* Am J Gastroenterol, 1998. **93**(2): p. 139-43.
8. Huang, P., et al., *Factors associated with driving in teens with autism spectrum disorders.* J Dev Behav Pediatr, 2012. **33**(1): p. 70-4.
9. Cox, N.B., et al., *Brief report: driving and young adults with ASD: parents' experiences.* J Autism Dev Disord, 2012. **42**(10): p. 2257-62.
10. Sterzing, P.R., et al., *Bullying involvement and autism spectrum disorders: prevalence and correlates of bullying involvement among adolescents with an autism spectrum disorder.* Arch Pediatr Adolesc Med, 2012. **166**(11): p. 1058-64.
11. Pan, C.Y., *Effects of water exercise swimming program on aquatic skills and social behaviors in children with autism spectrum disorders.* Autism, 2010. **14**(1): p. 9-28.
12. Papageorgiou, N., et al., *Divergent anti-inflammatory effects of different oil acute consumption on healthy individuals.* Eur J Clin Nutr, 2011. **65**(4): p. 514-9.
13. Das, U.N., *Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.* Lipids Health Dis, 2008. **7**: p. 37.
14. Chen, X., et al., *Interleukin-10 mediates the neuroprotection of hyperbaric oxygen therapy against traumatic brain injury in mice.* Neuroscience, 2014. **266**: p. 235-43.
15. Chen, L.F., et al., *Repetitive hyperbaric oxygen therapy provides better effects on brain inflammation and oxidative damage in rats with focal cerebral ischemia.* J Formos Med Assoc, 2014. **113**(9): p. 620-8.
16. Lavrnja, I., et al., *Repetitive hyperbaric oxygenation attenuates reactive astrogliosis and suppresses expression of inflammatory mediators in the rat model of brain injury.* Mediators Inflamm, 2015. **2015**: p. 498405.
17. Krajcovicova-Kudlackova, M., et al., *Plasma concentrations of selected antioxidants in autistic children and adolescents.* Bratisl Lek Listy, 2009. **110**(4): p. 247-50.
18. Taner, G., et al., *Modulating effects of pycnogenol(R) on oxidative stress and DNA damage induced by sepsis in rats.* Phytother Res, 2014. **28**(11): p. 1692-700.
19. Foundation, C. *Therapeutic Use Of Fish Oil for Apraxia, Autism and Other Communication Impairments*. Available from: <http://www.cherabfoundation.org/2014/therapeutic-use-of-fish-oil/>.
20. Chez, M.G., et al., *Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders.* J Child Neurol, 2002. **17**(11): p. 833-7.
21. Chen, X., et al., *Interleukin-10 mediates the neuroprotection of hyperbaric oxygen therapy against traumatic brain injury in mice.* Neuroscience, 2014. **266**: p. 235-43.
22. Chen, L.F., et al., *Repetitive hyperbaric oxygen therapy provides better effects on brain inflammation and oxidative damage in rats with focal cerebral ischemia.* J Formos Med Assoc, 2014. **113**(9): p. 620-8.
23. Chungpaibulpatana, J., et al., *Hyperbaric oxygen therapy in Thai autistic children.* J Med Assoc Thai, 2008. **91**(8): p. 1232-8.
24. Rossignol, D.A., et al., *Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial.* BMC Pediatr, 2009. **9**: p. 21.
25. Duan, S., et al., *Angiogenesis contributes to the neuroprotection induced by hyperbaric oxygen preconditioning against focal cerebral ischemia in rats.* Int J Neurosci, 2014.
26. Halepoto, D.M., L.Y. Al-Ayadhi, and A.A. Salam, *Therapeutic use of hyperbaric oxygen therapy for children with autism spectrum disorder.* J Coll Physicians Surg Pak, 2014. **24**(7): p. 508-14.
27. Moreira, P.I., et al., *CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats.* Exp Neurol, 2005. **196**(1): p. 112-9.
28. Paradies, G., et al., *The effect of aging and acetyl-L-carnitine on the pyruvate transport and oxidation in rat heart mitochondria.* FEBS Lett, 1999. **454**(3): p. 207-9.
29. Menor, C., et al., *Azathioprine acts upon rat hepatocyte mitochondria and stress-activated protein kinases leading to necrosis: protective role of N-acetyl-L-cysteine.* J Pharmacol Exp Ther, 2004. **311**(2): p. 668-76.
30. Arivazhagan, P., K. Ramanathan, and C. Panneerselvam, *Effect of DL-alpha-lipoic acid on mitochondrial enzymes in aged rats.* Chem Biol Interact, 2001. **138**(2): p. 189-98.
31. Liu, J. and B.N. Ames, *Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease.* Nutr Neurosci, 2005. **8**(2): p. 67-89.
32. Tandler, B., et al., *Riboflavin and mouse hepatic cell structure and function. II. Division of mitochondria during recovery from simple deficiency.* J Cell Biol, 1969. **41**(2): p. 477-93.
33. Liu, J. and B.N. Ames, *Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease.* Nutr Neurosci, 2005. **8**(2): p. 67-89.
34. Stenstrom, R., P.A. Bernard, and H. Ben-Simhon, *Exposure to environmental tobacco smoke as a risk factor for recurrent acute otitis media in children under the age of five years.* Int J Pediatr Otorhinolaryngol, 1993. **27**(2): p. 127-36.
35. Siegel, R.M., et al., *Treatment of otitis media with observation and a safety-net antibiotic prescription.* Pediatrics, 2003. **112**(3 Pt 1): p. 527-31.
36. McCormick, D.P., et al., *Nonsevere acute otitis media: a clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment.* Pediatrics, 2005. **115**(6): p. 1455-65.
37. Azarpazhooh, A., et al., *Xylitol for preventing acute otitis media in children up to 12 years of age.* Cochrane Database Syst Rev, 2011(11): p. CD007095.
38. Danhauer, J.L., et al., *Xylitol as a prophylaxis for acute otitis media: systematic review.* Int J Audiol, 2010. **49**(10): p. 754-61.
39. Danhauer, J.L., et al., *National survey of pediatricians' opinions about and practices for acute otitis media and xylitol use.* J Am Acad Audiol, 2010. **21**(5): p. 329-46.
40. Uhari, M., et al., *Xylitol chewing gum in prevention of acute otitis media: double blind randomised trial.* BMJ, 1996. **313**(7066): p. 1180-4.
41. Uhari, M., T. Kontiokari, and M. Niemela, *A novel use of xylitol sugar in preventing acute otitis media.* Pediatrics, 1998. **102**(4 Pt 1): p. 879-84.
42. Uhari, M., T. Tapiainen, and T. Kontiokari, *Xylitol in preventing acute otitis media.* Vaccine, 2000. **19 Suppl 1**: p. S144-7.
43. Bahrami, F., et al., *Kata techniques training consistently decreases stereotypy in children with autism spectrum disorder.* Res Dev Disabil, 2012. **33**(4): p. 1183-93.
44. Rindfleisch, T. *UW-L study: Martial arts benefit autistic kids*. 2010; Available from: <http://lacrossetribune.com/lifestyles/health-med-fit/uw-l-study-martial-arts-benefit-autistic-kids/article_d72b1520-07c0-11e0-b670-001cc4c03286.html>.
45. Legarda, S.B., et al., *Clinical neurofeedback: case studies, proposed mechanism, and implications for pediatric neurology practice.* J Child Neurol, 2011. **26**(8): p. 1045-51.
46. Hawkey, E. and J.T. Nigg, *Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials.* Clin Psychol Rev, 2014. **34**(6): p. 496-505.
47. Chovanova, Z., et al., *Effect of polyphenolic extract, Pycnogenol, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder.* Free Radic Res, 2006. **40**(9): p. 1003-10.
48. Trebaticka, J., et al., *Treatment of ADHD with French maritime pine bark extract, Pycnogenol.* Eur Child Adolesc Psychiatry, 2006. **15**(6): p. 329-35.
49. Viktorinova, A., et al., *Changed Plasma Levels of Zinc and Copper to Zinc Ratio and Their Possible Associations with Parent- and Teacher-Rated Symptoms in Children with Attention-Deficit Hyperactivity Disorder.* Biol Trace Elem Res, 2015.
50. Hongratanaworakit, T. and G. Buchbauer, *Relaxing effect of ylang ylang oil on humans after transdermal absorption.* Phytother Res, 2006. **20**(9): p. 758-63.
51. Buchbauer, G., et al., *Aromatherapy: evidence for sedative effects of the essential oil of lavender after inhalation.* Z Naturforsch C, 1991. **46**(11-12): p. 1067-72.
52. Kiecolt-Glaser, J.K., et al., *Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial.* Brain Behav Immun, 2011. **25**(8): p. 1725-34.
53. Amsterdam, J.D., et al., *A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder.* J Clin Psychopharmacol, 2009. **29**(4): p. 378-82.
54. Martin, F.P., et al., *Metabolic effects of dark chocolate consumption on energy, gut microbiota, and stress-related metabolism in free-living subjects.* J Proteome Res, 2009. **8**(12): p. 5568-79.
55. Wirtz, P.H., et al., *Dark chocolate intake buffers stress reactivity in humans.* J Am Coll Cardiol, 2014. **63**(21): p. 2297-9.
56. Koenig, K.P., A. Buckley-Reen, and S. Garg, *Efficacy of the Get Ready to Learn yoga program among children with autism spectrum disorders: a pretest-posttest control group design.* Am J Occup Ther, 2012. **66**(5): p. 538-46.
57. Whipple, J., *Music in intervention for children and adolescents with autism: a meta-analysis.* J Music Ther, 2004. **41**(2): p. 90-106.
58. Tanzer, J.M., *Xylitol chewing gum and dental caries.* Int Dent J, 1995. **45**(1 Suppl 1): p. 65-76.
59. Makinen, K.K., et al., *Xylitol chewing gums and caries rates: a 40-month cohort study.* J Dent Res, 1995. **74**(12): p. 1904-13.
60. Soderling, E., et al., *Influence of maternal xylitol consumption on mother-child transmission of mutans streptococci: 6-year follow-up.* Caries Res, 2001. **35**(3): p. 173-7.
61. Stensson, M., et al., *Oral administration of Lactobacillus reuteri during the first year of life reduces caries prevalence in the primary dentition at 9 years of age.* Caries Res, 2014. **48**(2): p. 111-7.
62. Singh, K., et al., *Sulforaphane treatment of autism spectrum disorder (ASD).* Proc Natl Acad Sci U S A, 2014. **111**(43): p. 15550-5.
63. Zhou, L. and J.A. Foster, *Psychobiotics and the gut-brain axis: in the pursuit of happiness.* Neuropsychiatr Dis Treat, 2015. **11**: p. 715-23.
64. Ianiro, G., et al., *Therapeutic modulation of gut microbiota: current clinical applications and future perspectives.* Curr Drug Targets, 2014. **15**(8): p. 762-70.
65. Archive, W.N. *Could a Tiny Worm Help Treat Autism?* 2013; Available from: <http://www.webmd.com/brain/autism/news/20131212/could-a-tiny-worm-help-treat-autism>.
66. Cannabis Science, I. and U.F.f. Autism. *Cannabis Science And The Unconventional Foundation For Autism (UF4A) Partner To Advance Successful Cannabis-Based Autism Treatments*. 2011; Available from: <http://www.medicalnewstoday.com/releases/219569.php>.
67. Onaivi, E.S., et al., *Consequences of cannabinoid and monoaminergic system disruption in a mouse model of autism spectrum disorders.* Curr Neuropharmacol, 2011. **9**(1): p. 209-14.
68. Dumont, G.J., et al., *Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration.* Soc Neurosci, 2009. **4**(4): p. 359-66.